CTL ELISPOT assay
- PMID: 25149304
- DOI: 10.1007/978-1-4939-1158-5_6
CTL ELISPOT assay
Abstract
Enzyme-linked immune absorbent spot (Elispot) is a quantitative method for measuring relevant parameters of T cell activation. The sensitivity of Elispot allows the detection of low-frequency antigen-specific T cells that secrete cytokines and effector molecules, such as granzyme B and perforin. Cytotoxic T cell (CTL) studies have taken advantage with this high-throughput technology by providing insights into quantity and immune kinetics. Accuracy, sensitivity, reproducibility, and robustness of Elispot resulted in a wide range of applications in research as well as in diagnostic field. Actually, CTL monitoring by Elispot is a gold standard for the evaluation of antigen-specific T cell immunity in clinical trials and vaccine candidates where the ability to detect rare antigen-specific T cells is of relevance for immune diagnostic. The most utilized Elispot assay is the interferon-gamma (IFN-γ) test, a marker for CD8(+) CTL activation, but Elispot can also be used to distinguish different subsets of activated T cells by using other cytokines such as T-helper (Th) 1-type cells (characterized by the production of IFN-γ, IL-2, IL-6, IL-12, IL-21, and TNF-α), Th2 (producing cytokines like IL-4, IL-5, IL-10, and IL-13), and Th17 (IL-17) cells. The reliability of Elispot-generated data, by the evaluation of T cell frequency recognizing individual antigen/peptide, is the core of this method currently applied widely to investigate specific immune responses in cancer, infections, allergies, and autoimmune diseases. The Elispot assay is competing with other methods measuring single-cell cytokine production, e.g., intracellular cytokine by FACS or Miltenyi cytokine secretion assay. Other types of lymphocyte frequency and function assays include limiting dilution assay (LDA), cytotoxic T cell assay (CTL), and tetramer staining. Compared with respect to sensitivity the Elispot assay is outranking other methods to define frequency of antigen-specific lymphocytes. The method described herein would like to offer helpful and clear protocols for researchers that apply Elispot. IFN-γ and perforin Elispot assays are described.
Similar articles
-
CTL ELISPOT Assay and T Cell Detection.Methods Mol Biol. 2021;2325:65-77. doi: 10.1007/978-1-0716-1507-2_5. Methods Mol Biol. 2021. PMID: 34053051
-
Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.J Immunol Methods. 2014 Jun;408:101-13. doi: 10.1016/j.jim.2014.05.011. Epub 2014 May 28. J Immunol Methods. 2014. PMID: 24877879
-
Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells.J Infect Dis. 2004 Nov 1;190(9):1692-6. doi: 10.1086/424490. Epub 2004 Sep 30. J Infect Dis. 2004. PMID: 15478077
-
New approaches for monitoring CTL activity in clinical trials.Adv Exp Med Biol. 2007;601:273-84. doi: 10.1007/978-0-387-72005-0_29. Adv Exp Med Biol. 2007. PMID: 17713015 Review.
-
Unique strengths of ELISPOT for T cell diagnostics.Methods Mol Biol. 2012;792:3-23. doi: 10.1007/978-1-61779-325-7_1. Methods Mol Biol. 2012. PMID: 21956497 Review.
Cited by
-
A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of Age.Vaccines (Basel). 2020 Jul 20;8(3):393. doi: 10.3390/vaccines8030393. Vaccines (Basel). 2020. PMID: 32698532 Free PMC article.
-
Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development.Front Immunol. 2023 Nov 23;14:1166059. doi: 10.3389/fimmu.2023.1166059. eCollection 2023. Front Immunol. 2023. PMID: 38077383 Free PMC article. Review.
-
Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines.Front Mol Biosci. 2021 Apr 15;8:623475. doi: 10.3389/fmolb.2021.623475. eCollection 2021. Front Mol Biosci. 2021. PMID: 33937323 Free PMC article. Review.
-
Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer.Front Immunol. 2023 May 3;14:1154818. doi: 10.3389/fimmu.2023.1154818. eCollection 2023. Front Immunol. 2023. PMID: 37207216 Free PMC article.
-
ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses.bioRxiv [Preprint]. 2022 Dec 27:2022.12.26.521940. doi: 10.1101/2022.12.26.521940. bioRxiv. 2022. Update in: Cell. 2023 May 25;186(11):2380-2391.e9. doi: 10.1016/j.cell.2023.04.024. PMID: 36597535 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials